112.13
3.25 (2.98%)
| Previous Close | 108.88 |
| Open | 109.93 |
| Volume | 467,631 |
| Avg. Volume (3M) | 1,135,591 |
| Market Cap | 6,440,157,184 |
| Price / Earnings (Forward) | 2.00 |
| Price / Sales | 14.03 |
| Price / Book | 8.67 |
| 52 Weeks Range | |
| Earnings Date | 29 Oct 2025 |
| Profit Margin | -30.57% |
| Operating Margin (TTM) | -19.39% |
| Diluted EPS (TTM) | -2.27 |
| Quarterly Revenue Growth (YOY) | 24.60% |
| Total Debt/Equity (MRQ) | 14.09% |
| Current Ratio (MRQ) | 6.49 |
| Operating Cash Flow (TTM) | -45.97 M |
| Levered Free Cash Flow (TTM) | -17.66 M |
| Return on Assets (TTM) | -6.68% |
| Return on Equity (TTM) | -20.36% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Devices (US) | Mixed | Mixed |
| Medical Devices (Global) | Mixed | Mixed | |
| Stock | Glaukos Corporation | Bullish | Bearish |
AIStockmoo Score
| Analyst Consensus | 1.5 |
| Insider Activity | NA |
| Price Volatility | 2.0 |
| Technical Moving Averages | 5.0 |
| Technical Oscillators | 4.0 |
| Average | 3.13 |
|
Glaukos Corp is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma. Its product pipeline also consists of an iStent SA trabecular micro-bypass system, a two-stent product that is slightly wider than the iStent Inject and uses a different auto-injection inserter designed for use in a standalone procedure. |
|
| Sector | Healthcare |
| Industry | Medical Devices |
| Investment Style | Small Growth |
| % Held by Insiders | 3.33% |
| % Held by Institutions | 101.71% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Brown Capital Management Llc | 30 Sep 2025 | 762,760 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 145.00 (UBS, 29.31%) | Buy |
| 145.00 (Truist Securities, 29.31%) | Buy | |
| Median | 123.50 (10.14%) | |
| Low | 103.00 (Goldman Sachs, -8.14%) | Buy |
| Average | 125.13 (11.59%) | |
| Total | 8 Buy | |
| Avg. Price @ Call | 99.01 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| UBS | 23 Dec 2025 | 145.00 (29.31%) | Buy | 116.18 |
| Truist Securities | 18 Dec 2025 | 145.00 (29.31%) | Buy | 113.21 |
| Citigroup | 11 Dec 2025 | 125.00 (11.48%) | Buy | 109.23 |
| 30 Oct 2025 | 113.00 (0.78%) | Buy | 87.80 | |
| Needham | 09 Dec 2025 | 125.00 (11.48%) | Buy | 106.87 |
| 30 Oct 2025 | 117.00 (4.34%) | Buy | 87.80 | |
| BTIG | 30 Oct 2025 | 116.00 (3.45%) | Buy | 87.80 |
| 20 Oct 2025 | 104.00 (-7.25%) | Buy | 79.47 | |
| JP Morgan | 30 Oct 2025 | 120.00 (7.02%) | Buy | 87.80 |
| Wells Fargo | 30 Oct 2025 | 122.00 (8.80%) | Buy | 87.80 |
| 27 Oct 2025 | 120.00 (7.02%) | Buy | 75.68 | |
| Goldman Sachs | 01 Oct 2025 | 103.00 (-8.14%) | Buy | 83.19 |
| Show more | ||||
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 16 Dec 2025 | Announcement | Glaukos Announces Participation in J.P. Morgan Healthcare Conference |
| 03 Nov 2025 | Announcement | Glaukos Announces Participation in Upcoming Investor Conferences |
| 29 Oct 2025 | Announcement | Glaukos Announces Third Quarter 2025 Financial Results |
| 20 Oct 2025 | Announcement | Glaukos Announces FDA Approval of Epioxa™ |
| 14 Oct 2025 | Announcement | Glaukos Innovation to be Highlighted at the 2025 American Academy of Ophthalmology Annual Meeting |
| 08 Oct 2025 | Announcement | Glaukos to Release Third Quarter 2025 Financial Results after Market Close on October 29 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |